001     142116
005     20240229105145.0
024 7 _ |a 10.1016/S1470-2045(18)30364-4
|2 doi
024 7 _ |a pmid:30102236
|2 pmid
024 7 _ |a 1470-2045
|2 ISSN
024 7 _ |a 1474-5488
|2 ISSN
024 7 _ |a altmetric:45910579
|2 altmetric
037 _ _ |a DKFZ-2018-02346
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Rutkowski, Stefan
|b 0
245 _ _ |a Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.
260 _ _ |a London
|c 2018
|b The Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660125052_9214
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Paediatric CNS tumours are the most common cause of childhood cancer-related morbidity and mortality, and improvements in their diagnosis and treatment are needed. New genetic and epigenetic information about paediatric CNS tumours is transforming the field dramatically. For most paediatric CNS tumour entities, subgroups with distinct biological characteristics have been identified, and these characteristics are increasingly used to facilitate accurate diagnoses and therapeutic recommendations. Future treatments will be further tailored to specific molecular subtypes of disease, specific tumour predisposition syndromes, and other biological criteria. Successful biomaterial collection is a key requirement for the application of contemporary methodologies for the validation of candidate prognostic factors, the discovery of new biomarkers, the establishment of appropriate preclinical research models for targeted agents, a quicker clinical implementation of precision medicine, and for other therapeutic uses (eg, for immunotherapies). However, deficits in organisational structures and interdisciplinary cooperation are impeding the collection of high-quality biomaterial from CNS tumours in most centres. Practical, legal, and ethical guidelines for consent, storage, material transfer, biobanking, data sharing, and funding should be established by research consortia and local institutions to allow optimal collection of primary and subsequent tumour tissue, body fluids, and normal tissue. Procedures for the collection and storage of biomaterials and related data should be implemented according to the individual and organisational structures of the local institutions.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Modena, Piergiorgio
|b 1
700 1 _ |a Williamson, Daniel
|b 2
700 1 _ |a Kerl, Kornelius
|b 3
700 1 _ |a Nysom, Karsten
|b 4
700 1 _ |a Pizer, Barry
|b 5
700 1 _ |a Bartels, Ute
|b 6
700 1 _ |a Puget, Stephanie
|b 7
700 1 _ |a Doz, François
|b 8
700 1 _ |a Michalski, Antony
|b 9
700 1 _ |a von Hoff, Katja
|b 10
700 1 _ |a Chevignard, Mathilde
|b 11
700 1 _ |a Avula, Shivaram
|b 12
700 1 _ |a Murray, Matthew J
|b 13
700 1 _ |a Schönberger, Stefan
|b 14
700 1 _ |a Czech, Thomas
|b 15
700 1 _ |a Schouten-van Meeteren, Antoinette Y N
|b 16
700 1 _ |a Kordes, Uwe
|b 17
700 1 _ |a Kramm, Christof M
|b 18
700 1 _ |a van Vuurden, Dannis G
|b 19
700 1 _ |a Hulleman, Esther
|b 20
700 1 _ |a Janssens, Geert O
|b 21
700 1 _ |a Solanki, Guirish A
|b 22
700 1 _ |a van Veelen, Marie-Luise C
|b 23
700 1 _ |a Thomale, Ulrich
|b 24
700 1 _ |a Schuhmann, Martin U
|b 25
700 1 _ |a Jones, Chris
|b 26
700 1 _ |a Giangaspero, Felice
|b 27
700 1 _ |a Figarella-Branger, Dominique
|b 28
700 1 _ |a Pietsch, Torsten
|b 29
700 1 _ |a Clifford, Steve C
|b 30
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 31
|u dkfz
700 1 _ |a Van Gool, Stefaan W
|b 32
773 _ _ |a 10.1016/S1470-2045(18)30364-4
|g Vol. 19, no. 8, p. e419 - e428
|0 PERI:(DE-600)2035574-9
|n 8
|p e419 - e428
|t The lancet / Oncology Oncology
|v 19
|y 2018
|x 1470-2045
909 C O |p VDB
|o oai:inrepo02.dkfz.de:142116
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET ONCOL : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b LANCET ONCOL : 2017
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21